Important note: Information in this article was accurate in October 2003. The state of the art may have changed since the publication date. |
AIDSWEEKLY Plus; Monday, October 6, 2003
Staff Medical Writers
"With both a vaccine and a microbicide many years down the road, we are hoping that this once-a-day pill - a potent, low-toxicity medication used in anti-HIV combination therapy - can be taken by uninfected people at high risk for HIV infection and will keep them from becoming infected," said study principal investigator, Kimberly Page Shafer, PhD, MPH, assistant professor of medicine at the UCSF Center for AIDS Prevention Studies (CAPS).
Although studies of tenofovir to prevent HIV transmission in animals have been promising, the effectiveness of this drug for preventing HIV-1 transmission in people is not known and will be evaluated in the planned research. The study will recruit 800 adult HIV-uninfected women who are at high risk for HIV infection. The study will be a randomized, double-blind clinical trial with participants chosen at random to receive either tenofovir or a placebo.
Participants will take one pill a day for 12 months. At the beginning and once a month during the trial, study subjects will receive counseling to reduce risky behavior, free condoms, and free screening and treatment of sexually transmitted infections.
Participants will be tested monthly for HIV and those who become infected during the study will be referred to an HIV treatment clinic for comprehensive care, including anti-HIV therapy if medically indicated. Effectiveness will be determined by comparing HIV infection rates between the group taking tenofovir and the one taking the placebo.
Study participants will be monitored for drug safety and adverse effects. Drug safety will be examined by comparing the occurrence of side effects in the group taking tenofovir with the one taking placebo.
The study will be conducted under the auspices of the Kingdom of Cambodia's Ministry of Health's National Center for HIV/AIDS, Dermatology and STDs in collaboration with researchers from UCSF and the University of New South Wales, Australia (UNSW). The study's grant award is for 3 years.
Funding for the study comes from two sources. NIH is funding UCSF, and the Bill and Melinda Gates Foundation is funding UNSW. Gilead, Inc., the manufacturer, is providing placebo and tenofovir at cost (per an arrangement for developing countries, including Cambodia), and no other support or assistance.
This article was prepared by AIDS Weekly editors from staff and other reports.
031006
AW031003
Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.